Concord Healthcare Group Co (HKSE:02453) Research & Development: HK$31.0 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02453 Concord Healthcare Group Co Ltd HKSE:02453
30 GF Score
Price HK$0.71
! 6 Warning Signs
View Full Analysis

What is Concord Healthcare Group Co Research & Development?

Concord Healthcare Group Co HKSE:02453 +1.43% 30 Research & Development is HK$31.0 Mil as of Dec. 2025. GuruFocus rates HKSE:02453 with a GF Score™ of 30/100. The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Concord Healthcare Group Co's Research & Development for the six months ended in Dec. 2025 was HK$16.1 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was HK$31.0 Mil.

Concord Healthcare Group Co  (HKSE:02453) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Concord Healthcare Group Co Research & Development Related Terms

Concord Healthcare Group Co Research & Development Historical Data

* Premium members only.

The historical data trend for Concord Healthcare Group Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Concord Healthcare Group Co Research & Development Chart

Concord Healthcare Group Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 49.45 46.14 39.86 33.29 31.12

Concord Healthcare Group Co Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.61 15.21 18.21 14.89 16.08
HKSE:02453
30GF Score
Concord Healthcare Group Co Ltd HKSE:02453
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Concord Healthcare Group Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$31.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of HK$31.0 Mil mean?
Concord Healthcare Group Co (HKSE:02453) has a Research & Development of HK$31.0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Concord Healthcare Group Co and its competitors.
Is Concord Healthcare Group Co's Research & Development too high?
Concord Healthcare Group Co's current Research & Development is HK$31.0 Mil. Overall, Concord Healthcare Group Co has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Concord Healthcare Group Co's Research & Development compare to HCA and THC?
Concord Healthcare Group Co's Research & Development of HK$31.0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Concord Healthcare Group Co and its competitors. Concord Healthcare Group Co's current Research & Development is HK$31.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Concord Healthcare Group Co stock overvalued right now?
Concord Healthcare Group Co (HKSE:02453) has a current Research & Development of HK$31.0 Mil. The current Research & Development is HK$31.0 Mil. Concord Healthcare Group Co's overall GF Score™ is 30/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Concord Healthcare Group Co (HKSE:02453), the current Research & Development is HK$31.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Concord Healthcare Group Co Business Description

Address No. 7 Guanghua Road, Room 26A1-26A5, East Tower, Hanwei Building, Chaoyang, Beijing, CHN, 100020
Concord Healthcare Group Co Ltd is a healthcare service provider in China that specializes in oncology. The Group owns and operates four offline self-operated medical institutions and one medical institution under construction, dedicated to providing comprehensive and specialized medical services to cancer patients. It also provides medical equipment, software, and related services to third-party medical institutions. The company's revenue is generated from its hospital business and its medical equipment, software, and related services segment. Substantially all of the company's revenue is generated from the PRC.
30GF Score

Get the complete analysis for HKSE:02453

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.71
Price